abstract |
The present invention relates to binding components specific for interleukin 1 receptor 1 (IL-1R1), in particular antibody molecules. For example, competes with IL-I and IL-1Ra for binding to IL-IRl, binding to IL-IRl in the following K D 10 pM when measured by Kinexa TM, specific for IL-IRl Isolated binding component. The binding component is useful for the treatment of disorders mediated by IL-1R1, including rheumatoid arthritis, asthma, and chronic obstructive pulmonary disease (COPD), among others. |